134 related articles for article (PubMed ID: 29341245)
1. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Clinical Drug-Drug Interactions of Elagolix, a Gonadotropin-Releasing Hormone Receptor Antagonist.
Polepally AR; Ng JW; Salem AH; Dufek MB; Parikh A; Carter DC; Kamradt K; Mostafa NM; Shebley M
J Clin Pharmacol; 2020 Dec; 60(12):1606-1616. PubMed ID: 33045114
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
[TBL] [Abstract][Full Text] [Related]
6. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
Tachibana M; Matsuki S; Maekawa Y; Kuroda K; Shimizu T; Tsutsumi J; Ishizuka H
Clin Transl Sci; 2023 Nov; 16(11):2153-2162. PubMed ID: 37705321
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Evaluation of the CYP3A4 and CYP2C9 Drug-Drug Interaction of Avacopan in 2 Open-Label Studies in Healthy Participants.
Miao S; Bekker P; Armas D; Lor M; Han Y; Webster K; Trivedi A
Clin Pharmacol Drug Dev; 2024 May; 13(5):517-533. PubMed ID: 38423992
[TBL] [Abstract][Full Text] [Related]
8. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.
Vishwanathan K; Dickinson PA; So K; Thomas K; Chen YM; De Castro Carpeño J; Dingemans AC; Kim HR; Kim JH; Krebs MG; Chih-Hsin Yang J; Bui K; Weilert D; Harvey RD
Br J Clin Pharmacol; 2018 Jun; 84(6):1156-1169. PubMed ID: 29381826
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
[TBL] [Abstract][Full Text] [Related]
10. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
[TBL] [Abstract][Full Text] [Related]
11. Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.
Khalilieh SG; Yee KL; Sanchez RI; Fan L; Anderson MS; Sura M; Laethem T; Rasmussen S; van Bortel L; van Lancker G; Iwamoto M
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30783000
[TBL] [Abstract][Full Text] [Related]
12. Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.
Ouellet D; Bramson C; Roman D; Remmers AE; Randinitis E; Milton A; Gardner M
Br J Clin Pharmacol; 2007 Jan; 63(1):59-66. PubMed ID: 16822276
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling to predict the clinical effect of azole antifungal agents as CYP3A inhibitors on azelnidipine pharmacokinetics.
Watanabe A; Kotsuma M
Drug Metab Pharmacokinet; 2024 Apr; 55():101000. PubMed ID: 38458122
[TBL] [Abstract][Full Text] [Related]
14. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
Garg V; Chandorkar G; Yang Y; Adda N; McNair L; Alves K; Smith F; van Heeswijk RP
Br J Clin Pharmacol; 2013 Feb; 75(2):431-9. PubMed ID: 22642697
[TBL] [Abstract][Full Text] [Related]
15. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
[TBL] [Abstract][Full Text] [Related]
16. Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.
Lim SYM; Al Bishtawi B; Lim W
Eur J Drug Metab Pharmacokinet; 2023 May; 48(3):221-240. PubMed ID: 37093458
[TBL] [Abstract][Full Text] [Related]
17. Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants.
Salerno SN; Edginton A; Gerhart JG; Laughon MM; Ambalavanan N; Sokol GM; Hornik CD; Stewart D; Mills M; Martz K; Gonzalez D;
Clin Pharmacol Ther; 2021 Jan; 109(1):253-262. PubMed ID: 32691891
[TBL] [Abstract][Full Text] [Related]
18. CYP3A inhibitor itraconazole affect pharmacokinetic behavior of famitinib and its active metabolite: results of a single-center, single-arm, open-label and fixed sequence study.
Huang Y; Jia Y; Chen X; Wang C; Wang Y; Wang M; Wu P; Shen J
Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):1005-1013. PubMed ID: 38053514
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug-Drug Interactions of Phenytoin.
Rodriguez-Vera L; Yin X; Almoslem M; Romahn K; Cicali B; Lukacova V; Cristofoletti R; Schmidt S
Pharmaceutics; 2023 Oct; 15(10):. PubMed ID: 37896246
[TBL] [Abstract][Full Text] [Related]
20. Real-world use of avatrombopag in patients with chronic liver disease and thrombocytopenia undergoing a procedure.
Satapathy SK; Sundaram V; Shiffman ML; Jamieson BD
Medicine (Baltimore); 2023 Oct; 102(40):e35208. PubMed ID: 37800793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]